Vascarta Advances VAS-101 as Non-Opioid Pain Therapy
SUMMIT, N.J., August 25, 2026 Vascarta Inc. outlined new and previously generated preclinical and clinical evidence supporting the potential...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SUMMIT, N.J., August 25, 2026 Vascarta Inc. outlined new and previously generated preclinical and clinical evidence supporting the potential...
BRISBANE, Calif., August 6, 2026 Pacira BioSciences announced the publication of positive two-year Phase 1 clinical trial results for...
NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...
LILLE & PARIS, France, Aug. 4, 2026 4Moving Biotech (4MB) announced the completion of patient enrollment in the Phase...
SAN DIEGO, California, July 2, 2026 Circular Genomics has unveiled CircPATHâ„¢, its proprietary circular RNA (circRNA) discovery and validation...
ROSEMONT, Illinois, July 2, 2026 The American Academy of Orthopaedic Surgeons (AAOS) has released its first-ever Clinical Practice Guideline...
SANDWICH, UK, June 3, 2026 Levicept Ltd announced new data from its Phase 2 clinical trial of LEVI-04, a...
PRINCETON, N.J., June 1, 2026 Made Scientific has been selected as the manufacturing partner for Columbia University’s NOVAKnee program,...
Boulder, Colorado, USA, April 6, 2026 $33.5M ARPA-H Funding Accelerates Regenerative Pipeline In a major boost to regenerative medicine...
Nes-Ziona, Israel — Nov. 24, 2025 — Enlivex Therapeutics Ltd. announced positive six-month topline results from the Phase IIa...
